Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt/Main, Frankfurt/Main, Germany.
Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany.
J Dtsch Dermatol Ges. 2023 Nov;21(11):1351-1357. doi: 10.1111/ddg.15191. Epub 2023 Oct 9.
Psoriatic arthritis (PsA) warrants early diagnosis and treatment for optimal results. This study aimed to elucidate routine monitoring activities for PsA with concurrent psoriasis (PsO) by dermatologists to gather data on how conditions for optimal treatment are ensured.
This non-interventional, prospective, epidemiological, cross-sectional study (2016-2019) included patients with confirmed PsA from dermatologists. Descriptive statistics were conducted for center and patient characteristics as well as for data of PsA monitoring and treatment stratified by different center types.
212 patients from 34 office-based physicians, five non-university hospitals, and nine university hospitals were included. The majority of the PsA patients were diagnosed by a rheumatologist (> 55% in each center type) at an early or intermediate stage (> 59%). Treatment was initiated most frequently by a dermatologist (office-based physicians: 69.6%, hospitals: 60.9%, university hospitals: 82.9%). Patients were treated with biologics more frequently in university hospitals (single therapy: 43.9%, in combination with systemic therapy: 26.8%) compared to private practices (single: 44.6%, combination: 13.5%) and non-university hospitals (single: 34.8%, combination: 8.7%).
As PsA diagnosis was performed most frequently by rheumatologists whereas treatment was primarily initiated by dermatologists, an optimal collaboration between these specialists is crucial.
银屑病关节炎(PsA)需要早期诊断和治疗以获得最佳效果。本研究旨在阐明皮肤科医生对并发银屑病(PsO)的 PsA 进行常规监测的活动,以收集有关如何确保最佳治疗条件的数据。
这是一项非干预性、前瞻性、流行病学、横断面研究(2016-2019 年),纳入了皮肤科医生确诊的 PsA 患者。对中心和患者特征以及按不同中心类型分层的 PsA 监测和治疗数据进行了描述性统计。
共纳入 34 名个体执业医生、5 家非大学医院和 9 家大学医院的 212 名患者。大多数 PsA 患者由风湿病学家(每种中心类型中>55%)在早期或中期(>59%)确诊。治疗最常由皮肤科医生(个体执业医生:69.6%,医院:60.9%,大学医院:82.9%)启动。与私人诊所(单药治疗:44.6%,联合治疗:13.5%)和非大学医院(单药治疗:34.8%,联合治疗:8.7%)相比,大学医院更频繁地用生物制剂治疗患者(单药治疗:43.9%,联合治疗:26.8%)。
由于 PsA 的诊断主要由风湿病学家进行,而治疗主要由皮肤科医生开始,因此这些专家之间的最佳协作至关重要。